Ovid Therapeutics and University of Connecticut Collaborate to Accelerate the Development of OV101 (gaboxadol) for Angelman Syndrome

 Ovid Therapeutics and University of Connecticut Collaborate to Accelerate the Development of OV101 (gaboxadol) for Angelman Syndrome

Shots:

  • Ovid will collaborate with UConn’s Stormy J. Chamberlain and secures exclusive access to identified genetic sequences for shRNA-based therapy. Ovid plans to leverage its translational medicine capabilities and drug development expertise in Angelman syndrome to advance OV101 into clinical
  • Ovid is developing OV101 for Angelman syndrome to restore tonic inhibition addressing several core symptoms of the disease. OV101 is currently being evaluated in P-III NEPTUNE study with expected results in Q4’20
  • Additionally, Ovid is exploring OV881, a microRNA approach that may reduce the expression of UBE3A-antisense and restores UBE3A expression while the company is developing OV935 (soticlestat) in collaboration with Takeda for rare developmental and epileptic encephalopathies (DEE)

Click here to read full press release/ article | Ref: Ovid Therapeutics | Image: Ovid Therapeutics

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post